Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum‐Based Therapy

• DOI: 10.1002/hed.28190
• Publication Date: 2025-05-20T10:04:03Z
• Authors: Tomomi Sanomachi; Tatsunori Shimoi; Yuki Kojima; Hideaki Takahashi; Motoko Arakaki; Asuka Kawachi; Hitomi Sumiyoshi ...; Mai Hoshino; Munehiro Ito; Ayumi Saito; Shosuke Kita; Aiko Maejima; Tadaaki Nishikawa; Kazuki Sudo; Taisuke Mori; Yasuhiro Fujiwara; Kan Yonemori

ABSTRACTBackgroundAdenoid cystic carcinoma (ACC) is the second most common and treatment‐resistant salivary gland carcinoma (SGC). Although platinum‐based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after platinum therapy remains unclear.MethodsWe retrospectively analyzed 19 patients with unresectable/metastatic ACC treated with platinum‐based therapy between December 2015 and January 2023 at the National Cancer Center Hospital, Japan. Ten patients received eribulin.ResultsThe median age was 61 years. 84% achieved disease control with the first‐line or later platinum‐based therapy (median progression‐free survival [mPFS]: 7.6 months). Second‐line or later eribulin monotherapy yielded a 50% disease control rate, with mPFS of 3.7 months and median overall survival of 41.7 months. The adverse events, predominantly neutropenia, were manageable.ConclusionEribulin shows promising effects of unresectable/metastatic ACC, offering tolerable adverse events.